Guardion Health Sciences (GHSI) Stock Forecast, Price Target & Predictions

GHSI Stock Forecast

Guardion Health Sciences stock forecast is as follows: an average price target of $0.01 (represents a -99.63% downside from GHSI’s last price of $3.22) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

GHSI Price Target

The average price target for Guardion Health Sciences (GHSI) is $0.01 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $0.01 to $0.01. This represents a potential -99.63% downside from GHSI's last price of $3.22.

GHSI Analyst Ratings

Buy

According to 1 Wall Street analysts, Guardion Health Sciences's rating consensus is 'Buy'. The analyst rating breakdown for GHSI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Guardion Health Sciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 09, 2022	Anthony Vendetti	Hovde Group	$0.01	-	156.19%	-99.63%

The latest Guardion Health Sciences stock forecast, released on Mar 09, 2022 by Anthony Vendetti from Hovde Group, set a price target of $0.01, which represents a 156.19% increase from the stock price at the time of the forecast (-), and a -99.63% decrease from GHSI last price ($3.22).

Guardion Health Sciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$3.22	$3.22	$3.22
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Guardion Health Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Guardion Health Sciences's last price of $3.22. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Mar 09, 2022	Maxim Group		Buy	Initialise

Guardion Health Sciences's last stock rating was published by Maxim Group on Mar 09, 2022. The company Initialise its GHSI rating from "null" to "Buy".

Guardion Health Sciences Financial Forecast

Guardion Health Sciences Revenue Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Revenue	-	-	-	-	-	$3.34M	$2.79M	$3.19M	$2.73M	$2.66M	$3.28M	$2.38M	$2.63M
Avg Forecast	$3.62M	$3.50M	$3.21M	$3.12M	$2.96M	$3.08M	$2.78M	$2.59M	$2.70M	$3.55M	$2.60M	$2.21M	$2.59M
High Forecast	$3.62M	$3.50M	$3.21M	$3.12M	$2.96M	$3.08M	$2.78M	$2.59M	$2.70M	$3.55M	$2.60M	$2.21M	$2.59M
Low Forecast	$3.62M	$3.50M	$3.21M	$3.12M	$2.96M	$3.08M	$2.78M	$2.59M	$2.70M	$3.55M	$2.60M	$2.21M	$2.59M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	1.08%	1.00%	1.23%	1.01%	0.75%	1.26%	1.08%	1.01%

Guardion Health Sciences's average Quarter revenue forecast for Dec 23 based on 1 analysts is $2.96M, with a low forecast of $2.96M, and a high forecast of $2.96M. GHSI's average Quarter revenue forecast represents a -11.21% decrease compared to the company's last Quarter revenue of $3.34M (Sep 23).

Guardion Health Sciences EBITDA Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	$-1.82M	$-752.52K	$-3.36M	$6.74M	$-1.41M	$-1.39M	$-2.25M	$-14.31M
Avg Forecast	$-2.80M	$-2.71M	$-2.48M	$-2.42M	$-2.29M	$-2.38M	$-2.15M	$-2.01M	$-2.09M	$-2.25M	$-1.65M	$-2.59M	$-1.64M
High Forecast	$-2.80M	$-2.71M	$-2.48M	$-2.42M	$-2.29M	$-2.38M	$-2.15M	$-2.01M	$-2.09M	$-2.25M	$-1.65M	$-2.07M	$-1.64M
Low Forecast	$-2.80M	$-2.71M	$-2.48M	$-2.42M	$-2.29M	$-2.38M	$-2.15M	$-2.01M	$-2.09M	$-2.25M	$-1.65M	$-3.10M	$-1.64M
Surprise %	-	-	-	-	-	0.76%	0.35%	1.67%	-3.22%	0.63%	0.85%	0.87%	8.71%

1 analysts predict GHSI's average Quarter EBITDA for Mar 23 to be $-2.01M, with a high of $-2.01M and a low of $-2.01M. This is -129.79% lower than Guardion Health Sciences's previous annual EBITDA (Dec 22) of $6.74M.

Guardion Health Sciences Net Income Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	$372.63K	$-1.17M	$2.53M	$-24.25M	$-1.66M	$-1.69M	$-2.64M	$-14.52M
Avg Forecast	$-359.56K	$-744.81K	$-847.54K	$-1.13M	$-937.43K	$-1.04M	$-1.19M	$-1.45M	$-1.93M	$-1.61M	$-2.89M	$-2.95M	$-50.72M
High Forecast	$-359.56K	$-744.81K	$-847.54K	$-1.13M	$-937.43K	$-1.04M	$-1.19M	$-1.45M	$-1.93M	$-1.61M	$-2.89M	$-2.36M	$-50.72M
Low Forecast	$-359.56K	$-744.81K	$-847.54K	$-1.13M	$-937.43K	$-1.04M	$-1.19M	$-1.45M	$-1.93M	$-1.61M	$-2.89M	$-3.53M	$-50.72M
Surprise %	-	-	-	-	-	-0.36%	0.98%	-1.74%	12.59%	1.04%	0.59%	0.90%	0.29%

Guardion Health Sciences's average Quarter net income forecast for Dec 23 is $-937.43K, with a range of $-937.43K to $-937.43K. GHSI's average Quarter net income forecast represents a -351.57% decrease compared to the company's last Quarter net income of $372.63K (Sep 23).

Guardion Health Sciences SG&A Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	$2.22M	$2.18M	$2.74M	$2.19M	$2.76M	$3.02M	$3.69M	$3.73M
Avg Forecast	$13.28M	$12.87M	$11.78M	$11.46M	$10.88M	$11.29M	$10.22M	$9.52M	$9.91M	$13.04M	$9.55M	$8.11M	$9.52M
High Forecast	$13.28M	$12.87M	$11.78M	$11.46M	$10.88M	$11.29M	$10.22M	$9.52M	$9.91M	$13.04M	$9.55M	$8.11M	$9.52M
Low Forecast	$13.28M	$12.87M	$11.78M	$11.46M	$10.88M	$11.29M	$10.22M	$9.52M	$9.91M	$13.04M	$9.55M	$8.11M	$9.52M
Surprise %	-	-	-	-	-	0.20%	0.21%	0.29%	0.22%	0.21%	0.32%	0.45%	0.39%

Guardion Health Sciences's average Quarter SG&A projection for Dec 23 is $10.88M, based on 1 Wall Street analysts, with a range of $10.88M to $10.88M. The forecast indicates a 389.51% rise compared to GHSI last annual SG&A of $2.22M (Sep 23).

Guardion Health Sciences EPS Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	$0.29	$-0.93	$2.00	$-19.85	$-1.35	$-1.37	$-3.37	$-0.01
Avg Forecast	$-0.28	$-0.58	$-0.66	$-0.88	$-0.73	$-0.81	$-0.93	$-1.13	$-1.50	$-1.25	$-2.25	$-4.00	$-39.50
High Forecast	$-0.28	$-0.58	$-0.66	$-0.88	$-0.73	$-0.81	$-0.93	$-1.13	$-1.50	$-1.25	$-2.25	$-4.00	$-39.50
Low Forecast	$-0.28	$-0.58	$-0.66	$-0.88	$-0.73	$-0.81	$-0.93	$-1.13	$-1.50	$-1.25	$-2.25	$-4.00	$-39.50
Surprise %	-	-	-	-	-	-0.36%	1.00%	-1.77%	13.23%	1.08%	0.61%	0.84%	0.00%

According to 1 Wall Street analysts, Guardion Health Sciences's projected average Quarter EPS for Dec 23 is $-0.73, with a low estimate of $-0.73 and a high estimate of $-0.73. This represents a -351.72% decrease compared to GHSI previous annual EPS of $0.29 (Sep 23).

Guardion Health Sciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVOK	Evoke Pharma	$4.59	$18.00	292.16%	Buy
AQST	Aquestive Therapeutics	$3.85	$10.00	159.74%	Buy
CYTH	Cyclo Therapeutics	$0.66	$0.95	43.94%	Buy
ORGO	Organogenesis	$3.57	$5.00	40.06%	Buy
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy

GHSI Forecast FAQ

Is Guardion Health Sciences a good buy?

Yes, according to 1 Wall Street analysts, Guardion Health Sciences (GHSI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of GHSI's total ratings.

What is GHSI's price target?

Guardion Health Sciences (GHSI) average price target is $0.012 with a range of $0.012 to $0.012, implying a -99.63% from its last price of $3.22. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Guardion Health Sciences stock go up soon?

According to Wall Street analysts' prediction for GHSI stock, the company can go down by -99.63% (from the last price of $3.22 to the average price target of $0.012), down by -99.63% based on the highest stock price target, and down by -99.63% based on the lowest stock price target.

Can Guardion Health Sciences stock reach $5?

GHSI's average twelve months analyst stock price target of $0.012 does not support the claim that Guardion Health Sciences can reach $5 in the near future.

What are Guardion Health Sciences's analysts' financial forecasts?

GHSI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $13.45M (high $13.45M, low $13.45M), average EBITDA is $-10.41M (high $-10.41M, low $-10.41M), average net income is $-3.082M (high $-3.082M, low $-3.082M), average SG&A $49.39M (high $49.39M, low $49.39M), and average EPS is $-2.4 (high $-2.4, low $-2.4).

Did the GHSI's actual financial results beat the analysts' financial forecasts?

Based on Guardion Health Sciences's last annual report (Dec 2023), the company's revenue was $12.25M, beating the average analysts forecast of $11.42M by 7.28%. Apple's EBITDA was $-4.336M, missing the average prediction of $-8.836M by -50.93%. The company's net income was $158.03K, missing the average estimation of $-4.623M by -103.42%. Apple's SG&A was $9.58M, missing the average forecast of $41.92M by -77.15%. Lastly, the company's EPS was $0, missing the average prediction of $-3.6 by -100.00%. In terms of the last quarterly report (Sep 2023), Guardion Health Sciences's revenue was $3.34M, beating the average analysts' forecast of $3.08M by 8.49%. The company's EBITDA was $-1.819M, missing the average prediction of $-2.381M by -23.60%. Guardion Health Sciences's net income was $372.63K, missing the average estimation of $-1.04M by -135.82%. The company's SG&A was $2.22M, missing the average forecast of $11.29M by -80.32%. Lastly, the company's EPS was $0.29, missing the average prediction of $-0.81 by -135.80%